



Spermosens receives patent approval in China

Spermosens AB ("Spermosens" or the "Company") today announces that the patent "Biosensor for Male Infertility" (ZL 2019800555646) has been granted in China. The patent covers the Company's method for measuring sperm binding to the egg receptor JUNO, a critical biological interaction during fertilization that no existing standard test can evaluate.

The patent granted in China further strengthens Spermosens' global intellectual property portfolio, which already includes granted patents in key markets including Europe, the United States of America, Japan, South Korea, Australia, South Africa, Hong Kong, Singapore, Canada, Mexico and Israel. The protection covers both the method and system underlying the JUNO-Checked technology, providing long-term exclusivity for the Company's approach to assessing critical sperm function.

Tore Duvold, CEO of Spermosens, comments: *"China is one of the world's largest and fastest-growing fertility markets, with a strong need for improved diagnostic tools. The granted patent represents an important step in securing our IP position for JUNO-Checked in a market with significant clinical activity. The technology offers a functional way to evaluate sperm and egg interaction, a key factor that cannot be assessed with today's conventional tests. The patent enables us to pursue dialogue with potential partners who could adapt and commercialize JUNO-Checked for clinical use in China."*

About JUNO-Checked

JUNO-Checked is a patented diagnostic technology developed by Spermosens to assess the ability of sperm cells to bind to the JUNO receptor on the egg. This is a crucial step in fertilization and cannot be evaluated with conventional semen analysis. By replicating this biological process in vitro, JUNO-Checked provides a direct functional measurement of sperm and egg binding. This offers new insight for the assessment of male fertility in IVF clinics and sperm banks.

About the Chinese Market

China is one of the largest fertility markets globally. More than 1 million assisted reproductive technology (ART) cycles are performed each year, resulting in over 300,000 ART-related births. The fertility services market was valued at approximately USD 3.3 billion in 2023 and is projected to reach USD 5.9 billion by 2030. Infertility affects an estimated 25 percent of couples trying to conceive, with male factors contributing significantly. Diagnostic semen analysis is routinely used in IVF clinics, hospital laboratories and sperm banks, representing a substantial addressable segment for advanced functional sperm tests such as JUNO-Checked.

References

- Grand View Research, China Fertility Services Market (2023–2030):
<http://www.grandviewresearch.com/horizon/outlook/fertility-services-market/china>
- Academic Publication, ART cycles and births in China:
http://academic.oup.com/humrep/article/38/Supplement_2/ii1/7425379
- PubMed, Prevalence of infertility in China:
<http://pubmed.ncbi.nlm.nih.gov/29030908>

For further information, please contact

Tore Duvold, CEO
Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, *JUNO-Checked*, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm egg binding capacity. *JUNO-Checked* supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com